Osimertinib and Ramucirumab Induced Pyogenic Granulomas: A Possible Synergistic Effect of Dual Oncologic Therapy

Division

West Florida

Hospital

Largo Medical Center

Document Type

Case Report

Publication Date

5-17-2021

Keywords

pyogenic granuloma, egfr, vegf, osimertinib, ramucirumab

Disciplines

Dermatology | Hemic and Lymphatic Diseases | Pathological Conditions, Signs and Symptoms | Skin and Connective Tissue Diseases

Abstract

Pyogenic granulomas represent benign vascular tumors that can present on the skin and mucous membranes. Multiple etiologic agents have been implicated in the pathogenesis including several systemic medications. Two notable oncologic therapies, epidermal growth factor receptor inhibitors and vascular endothelial growth factor receptor inhibitors, have each been associated with drug-induced pyogenic granulomas. We report a novel case report of dual therapy, medication-induced pyogenic granulomas. This likely represents a synergistic relationship between an epidermal growth factor receptor inhibitor, osimertinib, and a vascular endothelial growth factor receptor inhibitor, ramucirumab.

Publisher or Conference

Cureus

Link to Full Text

Share

COinS